Yayın:
Protective effect of silymarin on tacrolimus-induced kidney and liver toxicity

dc.contributor.authorTerzi, Funda
dc.contributor.authorÇiftçi, Mustafa Kemal
dc.date.accessioned2026-01-04T17:32:54Z
dc.date.issued2022-12-13
dc.description.abstractAbstract Background Tacrolimus (FK506) is an immunosuppressive agent and has toxic side effects such as nephrotoxicity, hepatotoxicity, and neurotoxicity. In our study, we aimed to investigate the protective effect of silymarin on renal and hepatic toxicity considered to be tacrolimus related. Methods In this 6-week experimental study, 46 eight-week-old healthy male rats were used. The groups comprised the Control (healthy rats, n = 6), Tac (tacrolimus 1 mg/kg, n = 8), silymarin 100 mg/kg (SLI 100 mg/kg n = 8), Tac + SLI 100 (tacrolimus 1 mg/kg + SLI 100 n = 8), SLI 200 (SLI 200 mg/kg n = 8), and Tac + SLI 200 (tacrolimus 1 mg/kg + SLI 200 mg/kg n = 8). After 6 weeks, all rats were sacrificed, and the tissue follow-up procedure was performed for kidney and liver tissues, histopathology, and in situ TUNEL analysis. Blood samples were analyzed for the total antioxidant capacity (TAC), total oxidant capacity (TOC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), albumin, total bilirubin, creatine. Results Histopathological findings of kidney and liver tissue of rats were determined to increase statistically in Tac group compared to SLI 1 00 and SLI 200 groups (P < 0.05). In addition, the Tac + SLI 100 and Tac + SLI 200 groups were found to be statistically similar to the Control group (P > 0.05). The in situ TUNEL method showed that the tacrolimus increased apoptosis while the silymarin decreased it. TOC levels increased statistically in Tac groups compared to silymarin-treated groups (P < 0.05). Although the TAC level was not statistically significant among the experimental groups (P > 0.05), the lowest was measured in the Tac group. The ALT, AST, GGT, total bilirubin, and creatine values were higher in the Tac group than in the silymarin groups (P < 0.05). There was no statistically significant difference between the groups with regard to the albumin level (P > 0.05). Conclusion In our study, we determined that tacrolimus caused damage to kidney and liver tissue. Histopathological, biochemical and apoptotic findings show that silymarin has a protective effect against nephrotoxicity and hepatotoxicity caused by tacrolimus.
dc.description.urihttps://doi.org/10.1186/s12906-022-03803-x
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/36514062
dc.description.urihttp://dx.doi.org/10.1186/s12906-022-03803-x
dc.description.urihttps://doaj.org/article/1d7843e74541443ab9ab3886fdd8e67b
dc.description.urihttps://hdl.handle.net/11363/6269
dc.identifier.doi10.1186/s12906-022-03803-x
dc.identifier.eissn2662-7671
dc.identifier.openairedoi_dedup___::334ae992faebd36ce0f3e52b4d3a4411
dc.identifier.pubmed36514062
dc.identifier.scopus2-s2.0-85144108769
dc.identifier.urihttps://hdl.handle.net/20.500.12597/40196
dc.identifier.volume22
dc.identifier.wos000898788700001
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.ispartofBMC Complementary Medicine and Therapies
dc.rightsOPEN
dc.subjectMale
dc.subjectResearch
dc.subjectHepatotoxicity
dc.subjectHistopathology
dc.subjectBilirubin
dc.subjectCreatine
dc.subjectKidney
dc.subjectTacrolimus
dc.subjectAntioxidants
dc.subjectRats
dc.subjectHepatitis
dc.subjectOther systems of medicine
dc.subjectAlbumins
dc.subjectRat
dc.subjectAnimals
dc.subjectChemical and Drug Induced Liver Injury
dc.subjectNephrotoxicity
dc.subjectTUNEL
dc.subjectRZ201-999
dc.subjectSilymarin
dc.subject.sdg3. Good health
dc.titleProtective effect of silymarin on tacrolimus-induced kidney and liver toxicity
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Terzi, Funda","name":"Funda","surname":"Terzi","rank":1,"pid":null},{"fullName":"Çiftçi, Mustafa Kemal","name":"Mustafa Kemal","surname":"Çiftçi","rank":2,"pid":null}],"openAccessColor":"gold","publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Male"},"provenance":null},{"subject":{"scheme":"FOS","value":"0301 basic medicine"},"provenance":null},{"subject":{"scheme":"FOS","value":"0303 health sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Research"},"provenance":null},{"subject":{"scheme":"keyword","value":"Hepatotoxicity"},"provenance":null},{"subject":{"scheme":"keyword","value":"Histopathology"},"provenance":null},{"subject":{"scheme":"keyword","value":"Bilirubin"},"provenance":null},{"subject":{"scheme":"keyword","value":"Creatine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Kidney"},"provenance":null},{"subject":{"scheme":"keyword","value":"Tacrolimus"},"provenance":null},{"subject":{"scheme":"keyword","value":"Antioxidants"},"provenance":null},{"subject":{"scheme":"keyword","value":"Rats"},"provenance":null},{"subject":{"scheme":"keyword","value":"Hepatitis"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null},{"subject":{"scheme":"keyword","value":"Other systems of medicine"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Albumins"},"provenance":null},{"subject":{"scheme":"keyword","value":"Rat"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals"},"provenance":null},{"subject":{"scheme":"keyword","value":"Chemical and Drug Induced Liver Injury"},"provenance":null},{"subject":{"scheme":"keyword","value":"Nephrotoxicity"},"provenance":null},{"subject":{"scheme":"keyword","value":"TUNEL"},"provenance":null},{"subject":{"scheme":"keyword","value":"RZ201-999"},"provenance":null},{"subject":{"scheme":"keyword","value":"Silymarin"},"provenance":null}],"mainTitle":"Protective effect of silymarin on tacrolimus-induced kidney and liver toxicity","subTitle":null,"descriptions":["<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Tacrolimus (FK506) is an immunosuppressive agent and has toxic side effects such as nephrotoxicity, hepatotoxicity, and neurotoxicity. In our study, we aimed to investigate the protective effect of silymarin on renal and hepatic toxicity considered to be tacrolimus related.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>In this 6-week experimental study, 46 eight-week-old healthy male rats were used. The groups comprised the Control (healthy rats, n = 6), Tac (tacrolimus 1 mg/kg, n = 8), silymarin 100 mg/kg (SLI 100 mg/kg n = 8), Tac + SLI 100 (tacrolimus 1 mg/kg + SLI 100 n = 8), SLI 200 (SLI 200 mg/kg n = 8), and Tac + SLI 200 (tacrolimus 1 mg/kg + SLI 200 mg/kg n = 8). After 6 weeks, all rats were sacrificed, and the tissue follow-up procedure was performed for kidney and liver tissues, histopathology, and in situ TUNEL analysis. Blood samples were analyzed for the total antioxidant capacity (TAC), total oxidant capacity (TOC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), albumin, total bilirubin, creatine.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Histopathological findings of kidney and liver tissue of rats were determined to increase statistically in Tac group compared to SLI 1 00 and SLI 200 groups (<jats:italic>P</jats:italic> &lt; 0.05). In addition, the Tac + SLI 100 and Tac + SLI 200 groups were found to be statistically similar to the Control group (<jats:italic>P</jats:italic> &gt; 0.05). The in situ TUNEL method showed that the tacrolimus increased apoptosis while the silymarin decreased it. TOC levels increased statistically in Tac groups compared to silymarin-treated groups (<jats:italic>P</jats:italic> &lt; 0.05). Although the TAC level was not statistically significant among the experimental groups (<jats:italic>P</jats:italic> &gt; 0.05), the lowest was measured in the Tac group. The ALT, AST, GGT, total bilirubin, and creatine values were higher in the Tac group than in the silymarin groups (<jats:italic>P</jats:italic> &lt; 0.05). There was no statistically significant difference between the groups with regard to the albumin level (<jats:italic>P</jats:italic> &gt; 0.05).</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>In our study, we determined that tacrolimus caused damage to kidney and liver tissue. Histopathological, biochemical and apoptotic findings show that silymarin has a protective effect against nephrotoxicity and hepatotoxicity caused by tacrolimus.</jats:p> </jats:sec>"],"publicationDate":"2022-12-13","publisher":"Springer Science and Business Media LLC","embargoEndDate":null,"sources":["Crossref","BMC Complement Med Ther","BMC Complementary Medicine and Therapies, Vol 22, Iss 1, Pp 1-10 (2022)"],"formats":["application/pdf"],"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"BMC Complementary Medicine and Therapies","issnPrinted":null,"issnOnline":"2662-7671","issnLinking":null,"ep":null,"iss":null,"sp":null,"vol":"22","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::334ae992faebd36ce0f3e52b4d3a4411","originalIds":["3803","10.1186/s12906-022-03803-x","50|doiboost____|334ae992faebd36ce0f3e52b4d3a4411","od_______267::b295ac87382f15a5cf0ebcf6b719675a","36514062","PMC9746137","oai:pubmedcentral.nih.gov:9746137","50|od_______267::b295ac87382f15a5cf0ebcf6b719675a","50|doajarticles::4c998592f3ed16a0576d78fab1d813b3","oai:doaj.org/article:1d7843e74541443ab9ab3886fdd8e67b","50|od______4470::e356eba77981d967bd4165db61375aa6","oai:acikerisim.gelisim.edu.tr:11363/6269"],"pids":[{"scheme":"doi","value":"10.1186/s12906-022-03803-x"},{"scheme":"pmid","value":"36514062"},{"scheme":"pmc","value":"PMC9746137"},{"scheme":"handle","value":"11363/6269"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":15,"influence":3.1019765e-9,"popularity":1.3472256e-8,"impulse":15,"citationClass":"C4","influenceClass":"C5","impulseClass":"C4","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1186/s12906-022-03803-x"}],"license":"CC BY","type":"Article","urls":["https://doi.org/10.1186/s12906-022-03803-x"],"publicationDate":"2022-12-13","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"36514062"},{"scheme":"pmc","value":"PMC9746137"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1186/s12906-022-03803-x"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/36514062"],"publicationDate":"2022-12-15","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1186/s12906-022-03803-x"}],"license":"CC BY","type":"Other literature type","urls":["http://dx.doi.org/10.1186/s12906-022-03803-x"],"publicationDate":"2022-12-13","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1186/s12906-022-03803-x"}],"type":"Article","urls":["https://doaj.org/article/1d7843e74541443ab9ab3886fdd8e67b"],"publicationDate":"2022-12-01","refereed":"nonPeerReviewed"},{"pids":[{"scheme":"handle","value":"11363/6269"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1186/s12906-022-03803-x"}],"license":"CC BY NC ND","type":"Article","urls":["https://hdl.handle.net/11363/6269"],"publicationDate":"2023-11-07","refereed":"nonPeerReviewed"}],"isGreen":true,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar